Skip to search formSkip to main contentSkip to account menu

LY335979

Known as: LY 335979 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Purpose: Our intention was to (a) to investigate the safety and tolerability of a potent P-glycoprotein modulator, zosuquidar… 
Review
2003
Review
2003
  • H. Thomas, H. Coley
  • Cancer control : journal of the Moffitt Cancer…
  • 2003
  • Corpus ID: 11595658
BACKGROUND Multidrug resistance (MDR) is a significant obstacle to providing effective chemotherapy to many patients… 
Highly Cited
2003
Highly Cited
2003
Our study examines the ability of LY335979 (Zosuquidar trihydrochloride) to modulate 3 distinct ABC transporters that are… 
Highly Cited
2003
Highly Cited
2003
The adequate distribution of STI-571 (Gleevec) to the central nervous system (CNS) is critical for its effective use in CNS… 
Highly Cited
2003
Highly Cited
2003
We determined the effect of zosuquidar·3HCl, an inhibitor of P-gp, on the penetration of the anticancer drug paclitaxel into the… 
Review
2001
Review
2001
Multidrug resistance may be conferred by P-glycoprotein (Pgp, ABCB1) or the multidrug resistance associated protein (MRP). These… 
Highly Cited
1999
Highly Cited
1999
Overexpression of ATP-dependent drug efflux pumps, P-glycoprotein (Pgp) or multidrug resistance-associated protein (MRP), confers… 
Highly Cited
1996
Highly Cited
1996
Overexpression of P-glycoprotein (Pgp) by tumors results in multidrug resistance (MDR) to structurally unrelated oncolytics. MDR…